734-936-8000 - Service Desk | Request Support

MSA Scientific Session Webinar: Anesthetic Implications for Marijuana Legalization in Michigan

To begin this activity, click Enroll. Once logged in, learners can access educational content, assessments, and evaluations. Learners who successfully complete the activity will be able to print a certificate.

Step Status
Educational Materials
Evaluation
Release Date: Thu, 11/5/20
Termination Date: Thu, 12/31/20
Credits: 1
Description:

MSA Scientific Session Webinar: Anesthetic Implications for Marijuana Legalization in Michigan

Presenter: Kevin Boehnke, PhD

This lecture was originally presented during Michigan Society of Anesthesiologists Scientific Session CME Activity held on 10/13/2020.
There are no relevant financial relationships to disclose for this activity.
Target Audience:

This activity is appropriate for Medical Students, Other Healthcare Professionals, Physicians in the fields of Anesthesiology.

Accreditation and Credit Designation:

Original Release Date: November 2020
Termination Date: November 2023

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Michigan Medical School and Michigan Society of Anesthesiologists. The University of Michigan Medical School is accredited by the ACCME to provide continuing medical education for physicians.

The University of Michigan Medical School designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification in Anesthesiology™ program and MOCA® are registered trademarks of The American Board of Anesthesiology®. This activity offers up to 1.0  CME credits, of which 1.0 credits contribute the patient safety CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology™ (MOCA®) program, known as MOCA 2.0®.

Please consult the ABA website, www.theABA.org, for a list of all MOCA 2.0 requirements

Additional Info:
  1. Wen H, Hockenberry JM. Association of Medical and Adult-Use Marijuana Laws With Opioid Prescribing for Medicaid Enrollees. JAMA Intern Med. 2018;178(5):673-679.
  2. Wen H, Hockenberry JM, Druss BG. The Effect of Medical Marijuana Laws on Marijuana-Related Attitude and Perception Among US Adolescents and Young Adults. Prev Sci. 2019;20(2):215-223.
  3. Bradford AC, Bradford WD. Medical Marijuana Laws Reduce Prescription Medication Use In Medicare Part D. Health Aff (Millwood). 2016;35(7):1230-1236.
  4. Bradford AC, Bradford WD. Medical Marijuana Laws May Be Associated With A Decline In The Number Of Prescriptions For Medicaid Enrollees. Health Aff (Millwood). 2017;36(5):945-951.
  5. Bradford AC, Bradford WD, Abraham A, Bagwell Adams G. Association Between US State Medical Cannabis Laws and Opioid Prescribing in the Medicare Part D Population. JAMA Intern Med. 2018;178(5):667-672.
  6. Shi Y. Medical marijuana policies and hospitalizations related to marijuana and opioid pain reliever. Drug Alcohol Depend. 2017;173:144-150.
  7. Shover CL, Davis CS, Gordon SC, Humphreys K. Association between medical cannabis laws and opioid overdose mortality has reversed over time. Proc Natl Acad Sci U S A. 2019;116(26):12624-12626.
  8. Bachhuber MA, Saloner B, Cunningham CO, Barry CL. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. JAMA Intern Med. 2014;174(10):1668-1673.
  9. Boehnke KF, Litinas E, Clauw DJ. Medical Cannabis Use Is Associated With Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients With Chronic Pain. J Pain. 2016;17(6):739-744.
  10. Boehnke KF, Scott JR, Litinas E, Sisley S, Williams DA, Clauw DJ. Pills to Pot: Observational Analyses of Cannabis Substitution Among Medical Cannabis Users With Chronic Pain. J Pain. 2019;20(7):830-841.
  11. Boehnke KF, Gangopadhyay S, Clauw DJ, Haffajee RL. Qualifying Conditions Of Medical Cannabis License Holders In The United States. Health Aff (Millwood). 2019;38(2):295-302.
  12. Lucas P, Baron EP, Jikomes N. Medical cannabis patterns of use and substitution for opioids & other pharmaceutical drugs, alcohol, tobacco, and illicit substances; results from a cross-sectional survey of authorized patients. Harm Reduct J. 2019;16(1):9.
  13. Reiman A, Welty M, Solomon P. Cannabis as a Substitute for Opioid-Based Pain Medication: Patient Self-Report. Cannabis Cannabinoid Res. 2017;2(1):160-166.
  14. Caputi TL, Humphreys K. Medical Marijuana Users are More Likely to Use Prescription Drugs Medically and Nonmedically. J Addict Med. 2018;12(4):295-299.
  15. Abuhasira R, Schleider LB, Mechoulam R, Novack V. Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. Eur J Intern Med. 2018;49:44-50.
  16. Campbell G, Hall WD, Peacock A, et al. Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. The Lancet Public Health. 2018;3(7):e341-e350.

Credits available:

ABA MOC Part II: 1.00
ABA MOC Part II Patient Safety: 1.00
AMA PRA Category 1: 1.00
Participation: 1.00